1. Introduction {#sec1}
===============

The novel betacoronavirus SARS-CoV-2 emerged in late 2019, causing an acute respiratory distress syndrome (ARDS) known as COVID-19. The risk of complications and mortality increases with age and significant comorbidities ([@bib5]), such as patients residing in long-term care facilities (LTCFs). Poor and vulnerable patient populations are disproportionately impacted by disasters such as the COVID-19 pandemic. Among those, patients with severe mental illness may be especially vulnerable due to a variety of factors including those relating to housing (housing insecurity or increased risk of exposure in residential treatment centers or prison settings) effects of underlying disease, side effects of medications, poor access to healthcare and lifestyle factors such as smoking ([@bib4]; [@bib1]). As of May 11, 2020, nearly 4.2 million patients have been infected with SARS-CoV-2 world-wide, many of whom are associated with LTCFs. Respiratory tract infections (RTIs) are a significant cause of death for patients with schizophrenia ([@bib14]; [@bib6]). Given the absence of effective treatment for COVID-19, factors that could exacerbate immune dysfunction in vulnerable patient populations require close scrutiny.

Atypical antipsychotic (AA) drugs are FDA-approved first line therapy for the treatment of schizophrenia, bipolar disorder, severe depression and irritability associated with autism. AA are prescribed off-label for diverse indications to non-psychotic patients including older adults, and are among the most highly prescribed medications across age ranges. In fact, up to one third of all LTCF patients are administered AA to control agitation and aggression associated with dementia, despite carrying a black box warning for sudden death in these patients ([@bib15]), and a small number of clinical reports associate AA with an increased risk of infection (most notably urinary; [@bib18]) and respiratory tract ([@bib17]) infections.

We previously reported global immunosuppression, myeloid dysplasia in the bone marrow, and thymic involution by the AA risperidone (RIS), and disruption of mitochondrial function and the cardio-immune axis by RIS and olanzapine in healthy individuals using a preclinical model ([@bib10]; [@bib2]; [@bib16]). However, the evidence for AA-associated immune dysregulation during acute or adaptive immune challenge is lacking. Therefore, the overarching goal of this work was to determine the effect of short-to moderate-term AA exposure on the ability to respond to immune challenge.

2. Materials and methods {#sec2}
========================

2.1. Animal care and use {#sec2.1}
------------------------

The Institutional Animal Care and Use Committee (IACUC) at the University of New England approved all animal studies.

The preclinical model used for this study employed 8 week old male C57BL/6J mice, fed standard mouse chow (18% protein rodent chow; Envigo) and treated by oral gavage once daily with vehicle (VEH; 0.1% acetic acid) or a low dose of RIS for 14 days (Sigma; 1 ​mg/kg). This drug dose was chosen based upon preliminary PK studies conducted in our laboratory ([@bib13]) which reflect plasma drug exposure consistent with what is observed clinically ([@bib9]). At the end of each treatment period, mice were sacrificed by CO~2~ asphyxiation and plasma (EDTA) was collected for analysis.

2.2. Drug exposure {#sec2.2}
------------------

Plasma concentrations of RIS and the active metabolite paliperidone (PAL) were measured at the time of necropsy to ensure proper dosing and drug metabolism. Concentrations of RIS and PAL were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis as previously reported ([@bib13]). Briefly, RIS and PAL were extracted from both plasma and bone marrow via protein precipitation with acetonitrile. Separation was accomplished using a Waters XBridge C18 analytical column (3.0 ​× ​50 ​mm, 3.5 ​μm). Mobile phase consisted of 0.1% formic acid in purified water (A) and 0.1% formic acid in acetonitrile (B). The flow rate was 0.4 ​mL/min, and heated to 60 ​°C. Gradient elution was employed, with initial conditions 95% A and 5% B. Solvent composition was held at the initial conditions for 1.0 ​min, and then was ramped over the following 1.5 ​min to 95% B. Composition was maintained at 95% B for 1 ​min. RIS and PAL were detected via an Agilent (Waldbronn, Germany) 6460 triple quadrupole mass spectrometer operated in positive ion MRM mode. The following transitions were monitored: RIS (411.2 ​→ ​191.0) and PAL (427.2 ​→ ​207.0).

2.3. Acute inflammatory challenge study {#sec2.3}
---------------------------------------

To assess the impact of RIS on the acute inflammatory response, RIS and ~D~VEH mice were given an intraperitoneal injection of either a sub lethal dose of lipopolysaccharide (LPS, 500 ​ng/kg, diluted in PBS; 14) or vehicle (~L~VEH, PBS) after 14 days of treatment ([@bib3]; [Supplemental Table S1](#appsec1){ref-type="sec"}). Two hours post-injection, mice were sacrificed by CO~2~ asphyxiation and blood was collected for subsequent analysis. Circulating cytokine, chemokine, and other immune factor levels were quantified using the Proteome Profiler Cytokine Array (R&D BioSystems) per the manufacturer's instructions. Arrays were imaged using a FluorChem Q instrument and quantified using ImageQuant v. 8.2. Each duplicate array spot representing a unique immune marker was normalized to each of three reference spots per array (N ​= ​3 measurements per spot). Normalized measurements were averaged for each spot, and the duplicate spots for each feature were then averaged to generate a total measure for each immune marker. Unique arrays were run for each animal. Statistical significance signaling a change in response to inflammatory challenge was determined for each immune factor by two-tailed *t-test* between ~D~VEH/~L~VEH and ~D~VEH/LPS groups, and RIS/~L~VEH and RIS/LPS groups. Factors with the same effect observed between ~D~VEH and RIS group relative to their respective controls were considered unaffected, whereas those with a different effect were considered dysregulated. Measured factors are listed in [Supplementary Table S2](#appsec1){ref-type="sec"}.

2.4. Immunological function pathway analysis {#sec2.4}
--------------------------------------------

Entries for all measured cytokines were accessed from the Kyoto Encyclopedia of Genes and Genomes (KEGG) Database ([@bib7]). Pathways for each measured factor involved in immune function (N ​= ​24 pathways) or response to respiratory tract infection (N ​= ​5 pathways) were pulled and analyzed. Pathways involving measured features that are not linked to immune function or infectious disease responses were not included in the analysis. Immune marker levels of ~D~VEH-treated mice following exposure to LPS relative to levels of ~D~VEH-treated mice following exposure to ~L~VEH were considered a normal, functional response (regardless of change). The numbers of immune markers in RIS-treated mice that had a normal response following exposure to LPS relative to RIS-treated, ~L~VEH-exposed mice (*i.e.*, that of ~D~VEH/LPS mice) were tabulated. RIS-treated mice that had a significantly different response from ~D~VEH/LPS mice were also tabulated. Heat maps reflecting the relative functionality and dysregulation of each KEGG pathway analyzed were generated. Each immune factor present at abnormal levels following LPS challenge during RIS treatment in a pathway was allotted proportional wavelength in their assigned color on a scale from 55 ​nm to 255 ​nm (dysregulated factors ​= ​red; factors at normal levels ​= ​green). Multiple factors contributing to either functionality or dysregulation contribute additively to color intensity.

2.5. Adaptive immune challenge study {#sec2.5}
------------------------------------

To assess the impact of RIS on adaptive immunity, RIS and ~D~VEH mice were immunized by intramuscular injection with either Pneumovax23® (VAX) or vehicle (~V~VEH, sterile water) after 5 days of treatment with RIS or ~D~VEH ([Table S1](#appsec1){ref-type="sec"}). Oral administration of RIS or ~D~VEH continued through day 14, when mice were sacrificed as described above. Anti-pneumococcal IgG antibodies were quantified by direct enzyme-linked immunosorbent assay (myBioSource) per manufacturer's instructions. Intensity of the chromogenic substrate 3,3′,5,5′-Tetramethylbenzidine plus 2N H~2~SO~4~ stop solution was detected using an M5 SpectraMax plate reader (optical density ƛ ​= ​450 ​nm). Statistical significance indicating a change in capacity for antibody production in response to vaccination was determined by one-tailed *t*-test between ~D~VEH/VAX and RIS/VAX groups. Individuals were defined as "responders" or "non-responders" by χ^2^ analysis between both ~D~VEH/~V~VEH and ~D~VEH/VAX groups and RIS/~V~VEH and RIS/VAX groups.

3. Results {#sec3}
==========

3.1. Animal health {#sec3.1}
------------------

The dose of drug selected for these studies results in total plasma drug concentrations that fall in the low end of the clinical range and causes no significant change in feeding, body weight or general behavior as previously published ([@bib2]; [@bib11], [@bib12], [@bib13]; [@bib10]). In all treatment cohorts, animals appeared healthy and gained weight, as expected.

In the [acute inflammatory challenge study,]{.ul} ~D~VEH/~L~VEH animals (n ​= ​6) weighed 25.1±1.3 on day 1 and 26.4±0.73 ​at the culmination of the study. ~D~VEH/LPS animals (n ​= ​6) weighed 24.0±1.14 ​g on day 1 and 25.8±1.16 ​g ​at the end of the study. RIS/~L~VEH animals (n ​= ​6) weighed 25.8±1.27 ​g on day 1 and 27.4±1.18 on the final day. RIS/LPS animals averaged 24.1±0.59 ​g BW on day 1 and 25.6±0.61 ​g on day last. The dose of LPS employed in this study is sub-lethal, and as expected, all animals survived LPS treatment. Plasma concentrations of RIS and PAL averaged 11.3±1.7 and 47.9±6.3 ​nM in RIS treated animals. No drug concentrations were detectable in samples from VEH treated animals.

In the [adaptive immune challenge study]{.ul}, average body weights on day 1 were 24.4±0.59, 24.2±1.17, 23.6±0.76 and 23.9±0.33 ​g for ~D~VEH/~V~VEH, ~D~VEH/VAX, RIS/~V~VEH and RIS/VAX animals, respectively (n ​= ​6 per treatment). Mean body weights on day 15 were 26.1±0.06, 26.2±1.05, 25.1±0.80 and 25.7±0.50 ​g for ~D~VEH/~V~VEH, ~D~VEH/VAX, RIS/~V~VEH and RIS/VAX animals (n ​= ​6 per treatment). Plasma concentrations of RIS and PAL averaged 12.6±2.9 and 47.1±5.7 ​nM in RIS treated animals. No drug concentrations were detectable in samples from VEH treated animals.

3.2. Acute inflammatory biomarkers {#sec3.2}
----------------------------------

Low-dose RIS treatment of previously healthy animals led to significant dysregulation of the acute inflammatory response upon challenge. Only 3 pathways (complement and coagulation cascades, Ras signaling pathway, and leukocyte transendothelial migration pathway) of 24 pathways were completely functional and all respiratory tract infection response pathways were at least partially dysregulated ([Fig. 1](#fig1){ref-type="fig"} ). Of the thirty-one cytokines assessed, nineteen were significantly altered/dysregulated in RIS/LPS individuals relative to ~D~VEH/LPS individuals, including the measurable clinical markers TNF-α and IL-6 ([Supplemental Table S2](#appsec1){ref-type="sec"}; [Supplemental Figure S1](#appsec1){ref-type="sec"}).Fig. 1**Innate Immunity is Confounded by the AA Risperidone**. The robustness of innate immunity was measured by introducing an acute inflammatory challenge, LPS, and measuring 31 circulating immune factors integral to several immune function and respiratory disease response pathways in the KEGG database. The number of factors in each pathway whose responses were dysregulated (red) or unaffected (green) by RIS relative to ~D~VEH controls were tabulated for each pathway. Only the complement and coagulation cascade, Ras signaling pathway, and leukocyte transendothelial migration pathways were unaffected by RIS, and all others showed some degree of dysregulation. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 1

3.3. Antibody response to immunization {#sec3.3}
--------------------------------------

Overall mean anti-pneumococcal antigen IgG response values for animals treated with ~D~VEH that received VAX injections generated were significantly (*P* ​\< ​0.0001) greater than ~D~VEH-treated mice receiving ~V~VEH, and significantly (*P* ​\< ​0.05) greater than mice treated with RIS prior to vaccination ([Fig. 2](#fig2){ref-type="fig"} a). Measured as individual responders, animals treated with RIS were significantly unable (*P* ​\< ​0.01) or less likely (*P* ​\< ​0.05) to mount an antibody response following immunization with Pneumovax23® relative to ~D~VEH treated controls ([Fig. 2](#fig2){ref-type="fig"}b).Fig. 2**Adaptive Immunity is Confounded by the AA Risperidone**. Functionality of adaptive immune responses was assessed by measuring antibody responses following vaccination. To determine the ability to mount an immune response to antigen, RIS and ~D~VEH mice were administered Pneumovax23 (VAX) or vehicle (vVEH, sterile water). Antibody titers against pneumococcal antigen were significantly diminished in RIS-treated individuals (**panel A**). Individuals' responder values (χ^2^) are shown, and black bars represent the group mean (**panel B**). No RIS-treated individuals were vaccine responders at the *P* ​\< ​0.01 level, and only one was a responder at the *P* ​\< ​0.05 level (red bars). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)Fig. 2

4. Discussion {#sec4}
=============

The data presented in this report, which were generated using a dose of RIS that results in low, clinically relevant plasma drug concentrations, are consistent with the hypothesis that the AA drug RIS is highly dysregulatory to the immune response during both acute and adaptive responses. The affinity of AA drugs for diverse G protein-coupled receptors (GPCRs) including dopaminergic, serotoninergic, alpha-adrenergic, histaminergic and muscarinic receptors and drug distribution to the bone marrow compartment suggest a mechanistic basis for immune cell effects as well as the neuronal cell effects for which they were designed ([@bib20]). Our previous preclinical studies demonstrated profound impact of AA administration on inflammatory and adaptive immune factors in multiple tissues (blood, heart, liver) in the absence of substantial immune challenge ([@bib10]; [@bib2]; [@bib16]). The COVID-19 pandemic led to an urgent need to evaluate the impact of AA drugs on innate and adaptive immune challenges in a controlled, preclinical setting.

In addition to high mortality rates associated with off-label AA use in LTCF patients, AA drugs have also been associated with a generally elevated risk for death by infection in psychiatric patients aged 50--60 years living on their own ([@bib8]). This suggests that it is plausible to expect a higher risk of mortality from COVID-19 infection in patients using AA drugs in an outpatient setting (for diverse psychiatric indications) as well as those in in-patient behavioral health centers, LTCFs, and the prison system. Our findings showing inflammatory and adaptive immune process dysregulation by RIS are especially troubling given the emerging understanding of inflammatory sepsis preceding rapid death in COVID-19 patients. Recent reports have implicated Toll-like receptor 4 (TLR4)-mediated signaling in patient responses to COVID-19, making our observations of dysregulated response to the TLR4 agonist LPS highly relevant. Cytokines and chemokines that increase during normal TLR4 signaling responses include TNF-α, IL-6, IL-1β, IL-12, IL-8, CCL5, MIP1-α, MIP1-β, CxCL10, CxCL9, and CxCL11 ([@bib7]). Of the 8 evaluated in this study, 3 (TNF-α, IL-6, and CxCL10) were significantly diminished by RIS and another 2 (MIP1-β and CxCL11) were dysregulated. Cytokines and chemokines reported to be elevated in COVID-19 patients include TNF-α, IL-6, IFNγ, CxCL10, CCL7, IL-1ra, CCL2, IL-1 α/β, MIP1-α, MIP1-β, IL-4, IL-10, and G-CSF ([@bib19]; [@bib22]). Of the 10 evaluated in this study, RIS significantly diminished 4 (TNF-α, IL-6, IFNγ, CxCL10, and CCL2) and dysregulated 4 (IL-1ra, IL-1α, IL-4, and MIP1-β). Only IL-10 and G-CSF levels were not altered by RIS during challenge with TLR4 agonist LPS, indicating that COVID-19 responses may be highly impacted by this drug. Furthermore, failure of RIS-treated mice to respond to immunization against pneumococcal antigen is alarming given the increasing concern about secondary bacterial pneumonia, including pneumococcal pneumonia, during ARDS due to SARS-CoV-2 ([@bib21]).

Taken together, our findings strongly indicate that consideration of AA use should be carefully weighed against the risk of adverse outcomes during infection in both outpatient and inpatient settings. Most notably, patients treated with AA medications in LTCFs, residential behavioral health treatment centers, group homes, or prisons must be carefully monitored during the COVID-19 pandemic.
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